Valuation: Verastem, Inc.

Market Cap 45Cr 39Cr 36Cr 33Cr 63Cr 4.27TCr 65Cr 434.55Cr 168.85Cr 2.09TCr 167.64Cr 163.96Cr 7.26TCr P/E 2026 *
-3.21x
P/E 2027 * -4.53x
Enterprise Value 28Cr 25Cr 23Cr 21Cr 40Cr 2.69TCr 41Cr 273.93Cr 106.44Cr 1.32TCr 105.67Cr 103.36Cr 4.58TCr EV / Sales 2026 *
2.76x
EV / Sales 2027 * 1.33x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day+4.74%
1 week+32.98%
Current month+32.98%
1 month+36.93%
3 months-6.79%
6 months-33.51%
Current year-34.20%
1 week 4.07
Extreme 4.07
5.14
1 month 3.43
Extreme 3.43
5.14
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
45.78
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Director/Board Member 60 26/05/2026
Director/Board Member 69 03/05/2017
Chairman 68 15/12/2025
Date Insider Type Main position Quantity % Market Cap.
22/06Sell

Chief Financial Officer

-4,089 0.0066%
22/06Sell

Chief Executive Officer

-20,871 0.0339%
21/05Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
+4.74%+32.98%+8.32%-36.50% 43Cr
-1.53%-1.43%+71.67%+129.70% 5.77TCr
-2.45%-7.32%+65.23%+83.15% 5.27TCr
+3.27%+9.29%+20.20%+486.76% 2.45TCr
-0.81%+0.52%-15.01%-12.47% 2.38TCr
-3.05%+3.06%+42.36%-5.66% 1.93TCr
-0.24%+5.40%+44.65%-26.41% 1.78TCr
+2.34%+14.18%+220.96%+380.99% 1.73TCr
-6.73%+9.90%+36.04% - 1.53TCr
-1.70%+3.12%+27.06%+190.57% 1.43TCr
Average -0.62%+7.37%+52.15%+132.24% 2.43TCr
Weighted average by Cap. -1.25%+2.75%+57.92%+141.33%

Financials

2026 *2027 *
Net sales 10Cr 8.94Cr 8.25Cr 7.62Cr 14Cr 975.44Cr 15Cr 99Cr 39Cr 477.34Cr 38Cr 37Cr 1.66TCr 18Cr 16Cr 14Cr 13Cr 25Cr 1.71TCr 26Cr 173.62Cr 67Cr 835.69Cr 67Cr 66Cr 2.9TCr
Net income -17Cr -15Cr -13Cr -12Cr -24Cr -1.59TCr -24Cr -162.14Cr -63Cr -780.45Cr -63Cr -61Cr -2.71TCr -14Cr -12Cr -12Cr -11Cr -20Cr -1.36TCr -21Cr -138.29Cr -54Cr -665.68Cr -53Cr -52Cr -2.31TCr
Net Debt -16Cr -14Cr -13Cr -12Cr -23Cr -1.58TCr -24Cr -160.62Cr -62Cr -773.15Cr -62Cr -61Cr -2.68TCr -21Cr -18Cr -17Cr -16Cr -30Cr -2.01TCr -30Cr -204.04Cr -79Cr -982.13Cr -79Cr -77Cr -3.41TCr
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
08/26/08 $5.080 +4.74% 43,46,707
07/26/07 $4.850 +8.74% 28,51,784
06/26/06 $4.460 -0.89% 18,11,512
02/26/02 $4.500 +9.76% 29,67,738
01/26/01 $4.100 +7.33% 21,86,504
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.080USD
Average target price
15.00USD
Spread / Average Target
+195.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock